Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade glioma (a type of brain cancer) and has also advanced to Phase II development for lung cancer. The company is further developing FG002, a preclinical-stage product that utilizes novel uPAR-targeted luminescent technology to enable surgeons to distinguish cancerous from healthy tissue during operations. FluoGuide A/S has established key collaborations, including an agreement with Linköping University Hospital to support the Phase I/II clinical evaluation of FG001 for the surgical removal of brain tumors, and an ongoing partnership with Copenhagen University Hospital. The company was founded in 2018 and maintains its headquarters in Copenhagen, Denmark.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of FLUO.ST is 51.3 and suggests 74.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i